Immunomagnetic Quantification of Circulating Tumor Cells as a Prognostic Factor of Androgen Deprivation Responsiveness in Patients With Hormone Naive Metastatic Prostate Cancer

Journal of Urology

Volumn 180, Issue 4, 2008, Pages 1342-1347

  Okegawa, Takatsugu ^a   Nutahara, Kikuo ^a   Higashihara, Eiji ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

neoplasm circulating cells; neoplasm metastasis; prostate specific antigen; prostatic neoplasms

Indexed keywords

ANDROGEN; BICALUTAMIDE; EPITHELIAL CELL ADHESION MOLECULE; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL ASSAY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TUMOR CELL; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; KAPLAN-MEIERS ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 50949132840     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.06.021     Document Type: Article

References (18)

1. Loberg R.D., Fridman Y., Pienta B.A., Keller E.T., McCauley L.K., Taichman R.S., et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia 6 (2004) 2004
2. Okegawa T., Noda H., Kato M., Miyata A., Nutahara K., and Higashihara E. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 44 (2000) 210
3. Alix-Panabieres C., Rebillard X., Brouillet J.P., Barbotte E., Iborra F., Segui B., et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem 51 (2005) 1538
4. O'Hara S.M., Moreno J.G., Zweitzig D.R., Gross S., Gomella L.G., and Terstappen L.W. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem 50 (2004) 826
5. Ylikoski A., Sjoroos M., Lundwall A., Karp M., Lovgren T., Lilja H., et al. Quantitative reverse transcription-PCR assay with an internal standard for the detection of prostate-specific antigen mRNA. Clin Chem 45 (1999) 1397
6. Kurek R., Ylikoski A., Renneberg H., Konrad L., Aumuller G., Roddiger S.J., et al. Quantitative PSA RT-PCR for preoperative staging of prostate cancer. Prostate 56 (2003) 263
7. Moreno J.G., O'Hara S.M., Gross S., Doyle G., Fritsche H., Gomella L.G., et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 58 (2001) 386
8. Kagan M., Howard D., Bendele T., Mayes J., Silvia J., Repollet M., et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 25 (2002) 104
9. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 (2004) 781
10. Cristofanilli M., Gonzalez-Angulo A., Sneige N., Kau S.W., Broglio K., Theriault R.L., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23 (2005) 1420
11. Moreno J.G., Miller M.C., Gross S., Allard W.J., Gomella L.G., and Terstappen L.W. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65 (2005) 713
12. Soloway M.S., Hardeman S.W., Hickey D., Raymond J., Todd B., Soloway S., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1998) 195
13. Hussain M., Tangen C.M., Higano C., Schelhammer P.F., Faulkner J., Crawford E.D., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984
14. Garcia J.A., Rosenberg J.E., Weinberg V., Scott J., Frohlich M., Park J.W., et al. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 99 (2007) 519
15. Kelly W.K., Scher H.I., Mazumdar M., Vlamis V., Schwartz M., and Fossa S.D. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11 (1993) 607
16. Ellis W.J., Pfitzenmaier J., Colli J., Arfman E., Lange P.H., and Vessella R.L. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 61 (2003) 277
17. Ghossein R.A., and Bhattacharya S. Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. Semin Surg Oncol 20 (2001) 304
18. Slovin S.F., and Scher H.I. Detectable tumor cells in the blood and bone marrow: smoke or fire?. Cancer 83 (1998) 394